%0 Clinical Trial, Phase I
%T Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
%A Brunner AM
%A Esteve J
%A Porkka K
%A Knapper S
%A Traer E
%A Scholl S
%A Garcia-Manero G
%A Vey N
%A Wermke M
%A Janssen JJWM
%A Narayan R
%A Fleming S
%A Loo S
%A Tovar N
%A Kontro M
%A Ottmann OG
%A Naidu P
%A Sun H
%A Han M
%A White R
%A Zhang N
%A Mohammed A
%A Sabatos-Peyton CA
%A Steensma DP
%A Rinne ML
%A Borate UM
%A Wei AH
%J Am J Hematol
%V 99
%N 2
%D 2024 02 22
%M 37994196
%F 13.265
%R 10.1002/ajh.27161
%X The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.